Positioning of proteasome inhibitors in therapy of solid malignancies

Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received con...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer chemotherapy and pharmacology Jg. 81; H. 2; S. 227 - 243
Hauptverfasser: Roeten, Margot S. F., Cloos, Jacqueline, Jansen, Gerrit
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2018
Springer Nature B.V
Schlagworte:
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer
Cancer Research
Colon
Cytotoxic Reviews
Drug Resistance, Neoplasm
Head & neck cancer
Humans
Medicine
Medicine & Public Health
Molecular modelling
Neoplasms - drug therapy
Oncology
Pancreas
Pharmacology/Toxicology
Protease inhibitors
Proteasome Endopeptidase Complex - chemistry
Proteasome Endopeptidase Complex - drug effects
Proteasome inhibitors
Proteasome Inhibitors - pharmacology
Proteasome Inhibitors - therapeutic use
Proteasomes
Review
Review Article
Solid tumors
Targeted cancer therapy
Ubiquitin
Carfilzomib
Bortezomib
Solid tumors
Drug resistance
Proteasome inhibitors
ISSN:0344-5704, 1432-0843, 1432-0843
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
AbstractList Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.
Author Roeten, Margot S. F.
Cloos, Jacqueline
Jansen, Gerrit
Author_xml – sequence: 1
  givenname: Margot S. F.
  surname: Roeten
  fullname: Roeten, Margot S. F.
  organization: Department of Hematology, VU University Medical Center
– sequence: 2
  givenname: Jacqueline
  orcidid: 0000-0001-9150-8026
  surname: Cloos
  fullname: Cloos, Jacqueline
  email: j.cloos@vumc.nl
  organization: Department of Hematology, VU University Medical Center, Department of Pediatric Oncology/Hematology, VU University Medical Center
– sequence: 3
  givenname: Gerrit
  surname: Jansen
  fullname: Jansen, Gerrit
  organization: Amsterdam Rheumatology and Immunology Center, Location VUmc, VU University Medical Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29184971$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtLAzEUhYNUtD5-gBsZcONm9GaSTJKNIMUXFHSh65DOZNqUmaQmU6H_3pRqqYKuEsh3Ts695wgNnHcGoTMMVxiAX0eAQkAOmOeECpnDHhpiSoocBCUDNARCac440EN0FOMcACgm5AAdFhILKjkeorsXH21vvbNumvkmWwTfGx19ZzLrZnZiex9iumb9zAS9WK2Z6FtbZ51u7dRpV1kTT9B-o9toTr_OY_R2f_c6eszHzw9Po9txXjFS9nlTTJgAIgnTABNZ10KzspCCi4qXuNGScDCaGEqYqEFj2hhKRY1pzTWjpCTH6Gbju1hOOlNXxvVBt2oRbKfDSnlt1c8XZ2dq6j8U41zgkiWDyy-D4N-XJvaqs7Eybaud8cuosORQcFxwkdCLX-jcL4NL4yWqlDTZcZqo891E2yjfG04A3gBV8DEG02wRDGrdotq0qFKLat2igqThvzSV7fW6pTSUbf9VFhtlTL-4qQk7of8UfQKuPLA6
CitedBy_id crossref_primary_10_1016_j_ica_2022_120929
crossref_primary_10_1074_jbc_RA118_003822
crossref_primary_10_1002_slct_202103455
crossref_primary_10_1002_jhet_3732
crossref_primary_10_3390_cancers12051207
crossref_primary_10_1016_j_drup_2019_100663
crossref_primary_10_1111_jns_12338
crossref_primary_10_3389_fmolb_2024_1351641
crossref_primary_10_3390_cancers12061532
crossref_primary_10_3390_cancers13081795
crossref_primary_10_7717_peerj_19235
crossref_primary_10_1002_iub_2937
crossref_primary_10_3390_ijms24065553
crossref_primary_10_3390_ijms24119382
crossref_primary_10_1007_s40005_021_00532_0
crossref_primary_10_1002_ctm2_70078
crossref_primary_10_1016_j_bbadis_2023_166884
crossref_primary_10_53941_ijddp_2024_100004
crossref_primary_10_1002_adhm_202201968
crossref_primary_10_3389_fmicb_2022_786008
crossref_primary_10_1038_s41598_020_71366_3
crossref_primary_10_1038_s41598_020_63275_2
crossref_primary_10_1016_j_trsl_2018_03_002
crossref_primary_10_1038_s41420_024_01817_7
crossref_primary_10_1038_s41598_024_67397_9
crossref_primary_10_1038_s41598_019_50840_7
crossref_primary_10_3390_biomedicines11123240
crossref_primary_10_3390_life12010042
crossref_primary_10_1007_s10787_024_01525_9
crossref_primary_10_1038_s41388_021_01696_7
crossref_primary_10_2174_1381612825666191106150018
crossref_primary_10_1016_j_ymgme_2019_01_007
crossref_primary_10_3390_antiox13070758
crossref_primary_10_3390_cells10030665
crossref_primary_10_1016_j_molcel_2020_05_035
crossref_primary_10_1038_s41598_019_41527_0
crossref_primary_10_1158_1078_0432_CCR_20_1232
crossref_primary_10_1007_s00436_020_06686_4
crossref_primary_10_1016_j_isci_2023_107777
crossref_primary_10_3390_cancers13102341
crossref_primary_10_1016_j_bcp_2018_12_006
crossref_primary_10_3390_biom11121789
crossref_primary_10_1016_j_jconrel_2019_11_031
crossref_primary_10_26508_lsa_201900562
crossref_primary_10_1016_j_pharmthera_2020_107579
crossref_primary_10_1186_s13062_023_00374_w
crossref_primary_10_1016_j_breast_2021_11_002
crossref_primary_10_1007_s10549_023_06878_3
crossref_primary_10_1016_j_drup_2019_100643
crossref_primary_10_1007_s12094_023_03349_5
crossref_primary_10_1016_j_drup_2019_100646
crossref_primary_10_1080_14728222_2019_1615884
crossref_primary_10_1038_s41598_020_58438_0
crossref_primary_10_3390_ijms20246112
crossref_primary_10_1016_j_xphs_2023_08_026
crossref_primary_10_3390_cancers12020401
crossref_primary_10_2147_IJN_S331210
crossref_primary_10_1016_j_yexcr_2024_114117
crossref_primary_10_3390_ijms22116144
crossref_primary_10_1007_s00018_020_03620_w
crossref_primary_10_1186_s12885_023_11689_2
crossref_primary_10_1093_carcin_bgae042
crossref_primary_10_1093_nar_gkac805
crossref_primary_10_1016_j_bbrc_2022_01_082
crossref_primary_10_1038_s41419_022_05117_9
crossref_primary_10_1016_j_tips_2023_05_006
crossref_primary_10_1186_s13046_022_02436_9
crossref_primary_10_1097_CAD_0000000000001735
crossref_primary_10_1158_1541_7786_MCR_20_0883
crossref_primary_10_1016_j_biopha_2018_04_030
crossref_primary_10_1002_1873_3468_14436
crossref_primary_10_3390_cancers10060155
crossref_primary_10_1007_s00280_020_04061_9
crossref_primary_10_1016_j_tranon_2022_101362
crossref_primary_10_1038_s41598_021_98450_6
crossref_primary_10_1080_02726351_2021_1906367
crossref_primary_10_3390_md22030114
crossref_primary_10_3390_cancers13061235
crossref_primary_10_1016_j_chembiol_2022_03_007
crossref_primary_10_1074_jbc_RA118_006290
crossref_primary_10_1038_s41420_019_0211_5
crossref_primary_10_3390_biom10040501
crossref_primary_10_1111_vco_12780
crossref_primary_10_1016_j_chembiol_2023_06_017
crossref_primary_10_1002_aoc_5120
crossref_primary_10_1080_13543776_2023_2272648
crossref_primary_10_3390_ijms21010327
crossref_primary_10_15252_emmm_202114740
crossref_primary_10_1002_eji_201847848
crossref_primary_10_1177_15330338231169870
crossref_primary_10_1016_j_bioorg_2023_106427
crossref_primary_10_1186_s40880_019_0424_2
crossref_primary_10_3390_ijms22168869
crossref_primary_10_1113_EP088762
Cites_doi 10.1007/s00280-016-2997-7
10.1158/1535-7163.MCT-08-0700
10.3324/haematol.2011.051169
10.3748/wjg.v20.i3.795
10.18632/oncotarget.4713
10.1002/cncr.23224
10.1016/j.drudis.2010.01.008
10.1016/j.yexcr.2012.04.003
10.1021/mp300044b
10.1146/annurev-biophys-051013-022958
10.1182/blood-2012-10-459883
10.2174/156800911794519716
10.1124/jpet.111.187542
10.1182/blood-2005-08-3531
10.1016/j.ymgme.2008.03.012
10.1093/jnci/djq198
10.1038/srep26456
10.1073/pnas.0511288103
10.1093/nar/gku763
10.1159/000011933
10.1016/j.chembiol.2016.12.016
10.1182/blood-2012-04-403733
10.1007/s11010-013-1939-5
10.1016/j.drup.2008.08.002
10.1021/mp2004143
10.1016/j.str.2014.11.019
10.1016/j.canlet.2015.06.023
10.1179/1973947813Y.0000000087
10.1038/nrc1361
10.1038/leu.2011.256
10.1200/JCO.2006.06.1853
10.1371/journal.pone.0027996
10.4161/cc.23882
10.1016/j.leukres.2009.07.022
10.1007/s00726-013-1648-0
10.1111/j.1365-2141.2005.05540.x
10.1038/nm.1978
10.1016/j.canlet.2015.05.025
10.1097/JTO.0b013e318267928d
10.1073/pnas.012485299
10.1038/nature05853
10.1038/sj.leu.2404444
10.1200/JCO.2011.37.8919
10.1016/j.drup.2005.12.001
10.1182/blood-2007-07-100651
10.1186/s13046-014-0111-8
10.1345/aph.1R561
10.1016/j.cellsig.2012.10.004
10.2217/14796694.3.1.83
10.1038/nrm2731
10.1016/0092-8674(94)90396-4
10.2174/156800911794519752
10.1182/blood-2010-04-276626
10.1016/j.cell.2010.07.036
10.1016/S0065-2776(02)80012-8
10.1097/JTO.0000000000000383
10.1186/bcr3175
10.1038/nm.2536
10.1016/j.lungcan.2005.01.006
10.1158/1535-7163.MCT-09-0239
10.1007/s00280-014-2451-7
10.3892/ijmm.2014.1678
10.3892/or.2015.4169
10.1111/j.1582-4934.2009.00832.x
10.1007/s10637-011-9766-6
10.1038/sj.cgt.7701029
10.1172/JCI0216886
10.4161/cbt.29452
10.1016/j.drup.2014.12.001
10.1371/journal.pone.0144825
10.1038/onc.2013.336
10.1054/drup.1999.0095
10.1016/j.biopha.2012.08.010
10.1186/1476-4598-6-73
10.1038/nrd1159
10.1016/j.chembiol.2012.01.003
10.3892/ol.2015.3047
10.1182/blood-2012-02-407999
10.1172/JCI0216784
10.1016/j.bbrc.2015.11.077
10.1128/MCB.24.22.9695-9704.2004
10.3109/10428194.2010.546015
10.1038/nrm2529
10.1158/1078-0432.CCR-11-0476
10.1158/1535-7163.MCT-07-2444
10.1111/j.1365-2141.2009.07803.x
10.18632/oncotarget.11340
10.2174/1381612811319220015
10.1186/1756-8722-3-13
10.1038/sj.leu.2402417
10.1158/1078-0432.CCR-10-1950
10.1016/j.molcel.2016.01.013
10.1080/17425247.2016.1178234
10.1016/j.tvjl.2013.08.003
10.1124/jpet.110.177824
10.1016/j.drup.2016.07.001
10.1158/0008-5472.CAN-05-2394
10.3324/haematol.2013.092411
10.1371/journal.pone.0073710
10.1038/cddis.2014.504
10.1074/jbc.M116.717793
10.1210/jc.2012-2679
10.1002/anie.201509092
10.1007/s12020-017-1256-y
10.1016/j.oraloncology.2012.01.012
10.1089/ars.2009.2501
10.2967/jnumed.111.101295
10.1016/j.bcp.2014.02.005
10.1007/s00280-013-2318-3
10.18632/oncotarget.6383
10.1038/cddis.2014.537
10.3324/haematol.2013.089334
10.1182/blood-2007-01-065888
10.3892/ijo.2016.3673
10.1186/bcr3575
10.1016/j.bbagen.2011.01.009
10.1016/j.ccr.2005.02.008
10.1152/physrev.00027.2001
10.1158/0008-5472.CAN-05-2961
10.1016/j.biomaterials.2013.09.098
10.1074/jbc.M609267200
10.1038/sj.onc.1210744
10.2353/ajpath.2007.070188
10.1371/journal.pone.0141681
10.1124/jpet.115.226993
10.1093/jnci/djr160
10.1530/ERC-14-0510
10.1038/onc.2010.566
10.1016/0955-0674(95)80031-X
10.1186/s40170-017-0169-9
10.18632/oncotarget.9222
10.1038/nri2687
10.1158/1078-0432.CCR-07-0061
10.1073/pnas.0709443104
10.1182/blood-2005-05-2091
10.1016/j.critrevonc.2012.08.001
10.1182/blood-2007-08-104950
10.1186/1756-8722-7-7
10.3109/10428194.2010.483303
10.1124/mol.114.092114
10.1158/0008-5472.CAN-06-4086
10.1007/s12185-016-2016-0
10.2174/1381612811319220012
10.1007/s10637-017-0441-4
10.1158/1078-0432.CCR-12-1213
10.2217/fon.14.30
10.2174/1568009614666140804154511
10.1016/j.bcp.2011.10.009
10.1200/JCO.2009.27.9158
10.1016/j.biopha.2015.12.010
10.1182/blood-2009-01-199604
10.1016/S1074-7613(02)00511-3
10.3892/or.2016.4873
10.1038/nrclinonc.2016.206
10.1039/C6BM00449K
10.1097/CAD.0b013e3283504e53
10.1016/j.leukres.2013.10.018
10.1038/srep15270
10.1038/cddis.2014.39
10.2147/BTT.S24580
10.1172/JCI200216886
10.1111/bjh.14014
10.18632/oncotarget.1060
10.3892/ijo.2011.1317
10.1016/j.clcc.2013.12.005
10.18632/oncotarget.4613
10.18632/oncotarget.7760
10.1007/s10555-017-9699-4
10.1007/s12079-011-0121-7
10.1182/blood-2012-02-407999.The
10.1172/JCI200216784
10.1128/MCB.24.22.9695
10.1002/HED
10.1124/jpet.110.177824.is
10.18632/oncotarget.12048
ContentType Journal Article
Copyright The Author(s) 2017
Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2017). All Rights Reserved.
Copyright_xml – notice: The Author(s) 2017
– notice: Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2017). All Rights Reserved.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8AO
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1007/s00280-017-3489-0
DatabaseName Springer Nature OA/Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Oncogenes and Growth Factors Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1432-0843
EndPage 243
ExternalDocumentID PMC5778165
29184971
10_1007_s00280_017_3489_0
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: Stichting Kinderen Kankervrij
  grantid: 140; 51
  funderid: http://dx.doi.org/10.13039/501100006244
– fundername: Egbers Foundation
– fundername: Cancer Center Amsterdam
  grantid: 07/36
– fundername: ;
– fundername: ;
  grantid: 07/36
– fundername: ;
  grantid: 140; 51
GroupedDBID ---
-53
-56
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
1N0
1SB
2.D
203
28-
29B
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
6PF
78A
7X7
88E
8AO
8C1
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFDYV
AFEXP
AFFNX
AFJLC
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
C6C
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M4Y
MA-
MK0
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P2P
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SBL
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
Y6R
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
~EX
~KM
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFFHD
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
CGR
CUY
CVF
ECM
EIF
NPM
7TO
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c536t-f2b5803935a00b9dd8a5629878c761fa9370ea3e4358d0a14fe448d14d7a54363
IEDL.DBID 8C1
ISICitedReferencesCount 112
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000423112600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0344-5704
1432-0843
IngestDate Tue Nov 04 01:54:41 EST 2025
Thu Oct 02 11:27:41 EDT 2025
Sat Nov 08 16:13:58 EST 2025
Mon Jul 21 06:04:39 EDT 2025
Tue Nov 18 22:08:06 EST 2025
Sat Nov 29 04:45:31 EST 2025
Fri Feb 21 02:33:14 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Carfilzomib
Bortezomib
Solid tumors
Drug resistance
Proteasome inhibitors
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c536t-f2b5803935a00b9dd8a5629878c761fa9370ea3e4358d0a14fe448d14d7a54363
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Literature Review-3
ObjectType-Review-3
content type line 23
ORCID 0000-0001-9150-8026
OpenAccessLink https://link.springer.com/10.1007/s00280-017-3489-0
PMID 29184971
PQID 1969416574
PQPubID 48447
PageCount 17
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5778165
proquest_miscellaneous_1970271278
proquest_journals_1969416574
pubmed_primary_29184971
crossref_primary_10_1007_s00280_017_3489_0
crossref_citationtrail_10_1007_s00280_017_3489_0
springer_journals_10_1007_s00280_017_3489_0
PublicationCentury 2000
PublicationDate 2018-02-01
PublicationDateYYYYMMDD 2018-02-01
PublicationDate_xml – month: 02
  year: 2018
  text: 2018-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Cancer chemotherapy and pharmacology
PublicationTitleAbbrev Cancer Chemother Pharmacol
PublicationTitleAlternate Cancer Chemother Pharmacol
PublicationYear 2018
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Chauhan, Singh, Aujay (CR76) 2010; 116
Lin, Chen, Chen (CR117) 2012; 48
Fennell, Chacko, Mutti (CR47) 2008; 27
de Bruin, Xin, Kraus (CR157) 2016; 55
Zaal, Wu, Jansen (CR167) 2017; 5
Denlinger, Meropol, Li (CR142) 2014; 13
Nooka, Gleason, Casbourne, Lonial (CR77) 2013; 7
Hochstrasser (CR3) 1995; 7
Huber, Heinemeyer, Groll (CR9) 2015; 23
Pandey, Nie, Batlevi (CR52) 2007; 447
Cron, Zhu, Kushwaha (CR91) 2013; 8
Lee, Levitsky, Parlati (CR158) 2016; 173
Zhang, Boufraqech, Lake, Kebebew (CR126) 2016; 7
Seifert, Bialy, Ebstein (CR159) 2010; 142
Dick, Fleming (CR70) 2010; 15
Gu, Bouwman, Greco (CR111) 2014; 5
Voortman, Checińska, Giaccone (CR79) 2007; 6
Zang, Thomas, Chan (CR119) 2012; 18
Jagannath, Durie, Wolf (CR56) 2005; 129
Li, Wood, Sprangers (CR168) 2010; 102
Witort, Lulli, Carloni, Capaccioli (CR132) 2013; 25
Yun, Kim, Tschida (CR160) 2016; 61
Kouroukis, Fernandez, Crump (CR74) 2011; 52
Ceresa, Giovannetti, Voortman (CR89) 2009; 8
Kuhn, Chen, Voorhees (CR66) 2007; 110
Micallef, Dharsee, Chen (CR166) 2010; 3
Millward, Price, Townsend (CR106) 2012; 30
Rastogi, Duggal, Singh (CR43) 2015; 6
Raz, Sheban, Gonen (CR162) 2014; 5
Fribley, Zeng, Wang (CR35) 2004; 24
Busse, Kraus, Na (CR30) 2008; 112
San-Miguel, Mateos (CR6) 2011; 96
Almond, Cohen (CR26) 2002; 16
Nencioni, Grünebach, Patrone (CR41) 2007; 21
Gatti, Zuco, Zaffaroni, Perego (CR42) 2013; 19
de Wilt, Jansen, Assaraf (CR29) 2012; 83
Kaufman (CR32) 2002; 110
Li, Hu, Li (CR95) 2017; 5
Yim, Yun, Lee (CR123) 2016; 469
Anderson (CR5) 2012; 30
Yang (CR136) 2012; 66
Ri (CR14) 2016; 104
Tan, Degenhardt, Nelson (CR45) 2005; 7
Ron (CR33) 2002; 110
Chen, Frezza, Schmitt (CR25) 2011; 11
Yu, Wan, Dutta (CR103) 2006; 103
Naumann, Schmich, Jaeger (CR104) 2012; 23
Weyburne, Wilkins, Sha (CR149) 2017; 24
Shen, Song, An (CR93) 2014; 35
Chattopadhyay, Berger, Koenig (CR139) 2015; 10
Ruschak, Slassi, Kay, Schimmer (CR64) 2011; 103
Shi, Yu, Wang (CR114) 2016; 7
CR59
Baker, Hanke, Sands (CR88) 2014; 33
Chauhan, Tian, Zhou (CR75) 2011; 17
Franke, Kaspers, Assaraf (CR163) 2016; 7
Moreau, Richardson, Cavo (CR61) 2015; 120
Zhu, Liu, Nie (CR85) 2015; 34
Huang, Yokomise, Miyatake (CR96) 2007; 3
Paramore, Frantz (CR37) 2003; 2
Piva, Ruggeri, Williams (CR72) 2008; 111
Arastu-Kapur, Anderl, Kraus (CR58) 2011; 17
Fanucchi, Fossella, Belt (CR80) 2006; 24
Buac, Shen, Schmitt (CR71) 2013; 19
Miyamoto, Hosotani, Wada (CR152) 1999; 56
Chaturvedi, Sung, Yadav (CR40) 2011; 30
Harousseau, Attal, Avet-Loiseau (CR55) 2010; 28
Kontopodis, Kotsakis, Kentepozidis (CR86) 2016; 77
Potts, Albitar, Anderson (CR67) 2011; 11
Tallóczy, Jiang, Virgin (CR53) 2002; 99
Modernelli, Naponelli, Giovanna Troglio (CR138) 2015; 5
Chiu, Lin, Lin (CR99) 2015; 365
Hitzerd, Verbrugge, Ossenkoppele (CR22) 2014; 46
Li, Li, Grandis, Johnson (CR44) 2008; 7
Maynadier, Basile, Gallud (CR116) 2016; 36
Verbrugge, Assaraf, Dijkmans (CR155) 2012; 341
Arnold, Chansky, Leggas (CR84) 2017; 35
Zang, Kirk, Johnson (CR153) 2014; 15
Huang, Wu, Zhou (CR13) 2014; 10
Kortuem, Stewart (CR62) 2013; 121
Allegra, Alonci, Gerace (CR60) 2014; 38
Zhang, Du, Meng (CR128) 2013; 98
Pérez-Galán, Roue, Villamor (CR36) 2006; 107
Jones, Moskaluk, Gillenwater (CR83) 2012; 7
Demo, Kirk, Aujay (CR65) 2007; 67
Mehta, Zhang, Boufraqech (CR124) 2015; 22
Wijdeven, Pang, Assaraf, Neefjes (CR1) 2016; 28
Green, Crews, Park (CR164) 2011; 1810
Zhao, Foster, Meyers (CR82) 2015; 10
Niewerth, Jansen, Riethoff (CR10) 2014; 86
Glickman, Ciechanover (CR20) 2002; 82
Williamson, Silva, Terkelsen (CR81) 2009; 8
Selimovic, Porzig, El-Khattouti (CR144) 2013; 25
Wang, Yu, Jiang (CR115) 2016; 6
Chen, Yeh, Yu (CR109) 2013; 15
McConkey, Zhu (CR39) 2008; 11
Niewerth, van Meerloo, Jansen (CR147) 2014; 89
Muchamuel, Basler, Aujay (CR161) 2009; 15
Tseng, Liu, Chang (CR108) 2012; 14
Chen, Wu, Shen (CR129) 2016; 379
Nawrocki, Carew, Dunner (CR98) 2005; 65
Rock, York, Saric, Goldberg (CR24) 2002; 80
CR112
Adams (CR19) 2004; 4
Simms-waldrip, Rodriguez-gonzalez, Lin (CR51) 2008; 94
Chen, Thai, Yoneda (CR165) 2014; 33
Obeng, Carlson, Gutman (CR31) 2006; 107
Chang, Huang, Chen (CR110) 2014; 5
Groettrup, Kirk, Basler (CR28) 2010; 10
Ito, Kobayashi, Kuroki (CR143) 2013; 198
Dou, Li (CR4) 1999; 2
Kisselev, Van Der Linden, Overkleeft (CR68) 2012; 19
Neukirchen, Meier, Rohrbeck (CR97) 2007; 14
Suzuki, Demo, Deu (CR148) 2011; 6
Qiang, Sui, Ma (CR127) 2017; 56
Mortenson, Schlieman, Virudachalam (CR92) 2005; 49
Berkers, Leestemaker, Schuurman (CR73) 2012; 9
Jagannath, Durie, Wolf (CR57) 2009; 146
Chang, Wang (CR122) 2016; 291
Manasanch, Orlowski (CR27) 2017; 14
Fang, Rhyasen, Bolanos (CR100) 2012; 120
Sung, Park, Choi (CR121) 2012; 318
Carew, Medina, Esquivel (CR54) 2010; 14
Komander, Clague, Urbé (CR17) 2009; 10
Shimizu, Hendershot (CR34) 2009; 11
Miyahara, Kazama, Kokuba (CR113) 2016; 49
Ao, Wu, Kim (CR154) 2012; 9
Oerlemans, Franke, Assaraf (CR156) 2008; 112
Corso, Mangiacavalli, Varettoni (CR11) 2010; 34
Thompson (CR78) 2013; 47
Chen, Yang, Pan (CR133) 2016; 77
Li, Lu, Sun (CR137) 2015; 10
Coelho, Almeida, Santos-Silva (CR107) 2016; 13
Moiseeva, Bottrill, Melino, Barlev (CR21) 2013; 44
Ding, Ni, Gao (CR48) 2007; 171
Cloos, Roeten, Franke (CR7) 2017
Niewerth, Franke, Jansen (CR150) 2013; 98
Niewerth, Kaspers, Assaraf (CR146) 2014; 7
Li, Johnson (CR118) 2013; 12
Wirth, Stojanovic, Christian (CR46) 2014; 42
Ao, Reichel, Hu (CR94) 2015; 355
Baiz, Dapas, Farra (CR131) 2014; 20
Ding, Ni, Gao (CR49) 2007; 282
Franke, Niewerth, Assaraf (CR145) 2012; 26
Gilbert, Lee, Argiris (CR120) 2012; 341
de Wilt, Kroon, Jansen (CR90) 2013; 85
Gong, Yang, Xu (CR105) 2014; 73
Krȩtowski, Borzym-Kluczyk, Cechowska-Pasko (CR140) 2014; 389
Siegel, Martin, Nooka (CR63) 2013; 98
Liu, Gao, Yang (CR134) 2015; 9
Reits, Griekspoor, Neijssen (CR23) 2003; 18
Hideshima, Ikeda, Chauhan (CR38) 2009; 114
Altmann, Markert, Askoxylakis (CR125) 2012; 53
Dou, Zonder (CR2) 2014; 14
Nguyen, Marcellus, Roulston (CR151) 2007; 104
Singha, Gatla, Phyo, Patel (CR141) 2015; 6
Ciechanover (CR15) 1994; 79
Niewerth, Jansen, Assaraf (CR8) 2015; 18
Nawrocki, Carew, Pino (CR50) 2006; 1
Obaidat, Weiss, Wahlgren (CR69) 2011; 337
Kroemer, Levine (CR102) 2008; 9
Voortman, Smit, Honeywell (CR87) 2007; 13
Dang, Wen, Yang (CR135) 2014; 33
Cavaletti, Jakubowiak (CR12) 2010; 51
Vandewynckel, Coucke, Laukens (CR130) 2016; 7
Demarchi, Brancolini (CR16) 2005; 8
Streich, Lima (CR18) 2014; 43
Min, Xu, Chen (CR101) 2014; 74
Arcy, Brnjic, Olofsson (CR169) 2011; 17
JF San-Miguel (3489_CR6) 2011; 96
SC Coelho (3489_CR107) 2016; 13
S Jagannath (3489_CR57) 2009; 146
D Siegel (3489_CR63) 2013; 98
ES Sung (3489_CR121) 2012; 318
L Zhang (3489_CR126) 2016; 7
MM Mortenson (3489_CR92) 2005; 49
T Simms-waldrip (3489_CR51) 2008; 94
JS Carew (3489_CR54) 2010; 14
3489_CR59
D Baiz (3489_CR131) 2014; 20
SJ Lee (3489_CR158) 2016; 173
H Wang (3489_CR115) 2016; 6
T Muchamuel (3489_CR161) 2009; 15
MP Fanucchi (3489_CR80) 2006; 24
DR Jones (3489_CR83) 2012; 7
SM Hitzerd (3489_CR22) 2014; 46
NE Franke (3489_CR145) 2012; 26
DA Fennell (3489_CR47) 2008; 27
J Cloos (3489_CR7) 2017
3489_CR112
B Singha (3489_CR141) 2015; 6
Y Shi (3489_CR114) 2016; 7
E Suzuki (3489_CR148) 2011; 6
G Bruin de (3489_CR157) 2016; 55
SM Arnold (3489_CR84) 2017; 35
D Chauhan (3489_CR76) 2010; 116
EM Huber (3489_CR9) 2015; 23
P Moreau (3489_CR61) 2015; 120
PD Arcy (3489_CR169) 2011; 17
WX Ding (3489_CR49) 2007; 282
U Seifert (3489_CR159) 2010; 142
N Chattopadhyay (3489_CR139) 2015; 10
L Ao (3489_CR154) 2012; 9
G Kroemer (3489_CR102) 2008; 9
JL Thompson (3489_CR78) 2013; 47
MJ Williamson (3489_CR81) 2009; 8
J Gilbert (3489_CR120) 2012; 341
Y Gu (3489_CR111) 2014; 5
NE Franke (3489_CR163) 2016; 7
E Kontopodis (3489_CR86) 2016; 77
LHAM Wilt de (3489_CR90) 2013; 85
M Nguyen (3489_CR151) 2007; 104
C Potts (3489_CR67) 2011; 11
M Wirth (3489_CR46) 2014; 42
Z Tallóczy (3489_CR53) 2002; 99
KM Kortuem (3489_CR62) 2013; 121
J Micallef (3489_CR166) 2010; 3
HW Chiu (3489_CR99) 2015; 365
KC Anderson (3489_CR5) 2012; 30
D Niewerth (3489_CR10) 2014; 86
S Raz (3489_CR162) 2014; 5
A Paramore (3489_CR37) 2003; 2
A Mehta (3489_CR124) 2015; 22
A Fribley (3489_CR35) 2004; 24
DJ McConkey (3489_CR39) 2008; 11
FC Streich (3489_CR18) 2014; 43
QP Dou (3489_CR4) 1999; 2
ST Nawrocki (3489_CR98) 2005; 65
E Witort (3489_CR132) 2013; 25
P Pérez-Galán (3489_CR36) 2006; 107
D Komander (3489_CR17) 2009; 10
YJ Chen (3489_CR129) 2016; 379
I Chang (3489_CR122) 2016; 291
L Gatti (3489_CR42) 2013; 19
D Li (3489_CR137) 2015; 10
CT Kouroukis (3489_CR74) 2011; 52
L Ao (3489_CR94) 2015; 355
Y Zang (3489_CR119) 2012; 18
E Reits (3489_CR23) 2003; 18
K Ito (3489_CR143) 2013; 198
AM Ruschak (3489_CR64) 2011; 103
SE Verbrugge (3489_CR155) 2012; 341
D Niewerth (3489_CR147) 2014; 89
R Oerlemans (3489_CR156) 2008; 112
JL Harousseau (3489_CR55) 2010; 28
L Yu (3489_CR103) 2006; 103
HY Zhang (3489_CR128) 2013; 98
T Tan (3489_CR45) 2005; 7
Y Shimizu (3489_CR34) 2009; 11
CH Chen (3489_CR165) 2014; 33
K Miyahara (3489_CR113) 2016; 49
CR Berkers (3489_CR73) 2012; 9
G Cavaletti (3489_CR12) 2010; 51
A Corso (3489_CR11) 2010; 34
Y Miyamoto (3489_CR152) 1999; 56
ST Nawrocki (3489_CR50) 2006; 1
M Hochstrasser (3489_CR3) 1995; 7
A Allegra (3489_CR60) 2014; 38
ES Weyburne (3489_CR149) 2017; 24
YJ Chen (3489_CR109) 2013; 15
J Shen (3489_CR93) 2014; 35
AF Kisselev (3489_CR68) 2012; 19
S Jagannath (3489_CR56) 2005; 129
A Obaidat (3489_CR69) 2011; 337
L Gong (3489_CR105) 2014; 73
D Niewerth (3489_CR150) 2013; 98
A Busse (3489_CR30) 2008; 112
W-X Ding (3489_CR48) 2007; 171
M Groettrup (3489_CR28) 2010; 10
M Millward (3489_CR106) 2012; 30
A Ciechanover (3489_CR15) 1994; 79
M Ri (3489_CR14) 2016; 104
A Nencioni (3489_CR41) 2007; 21
TD Green (3489_CR164) 2011; 1810
C Li (3489_CR95) 2017; 5
A Modernelli (3489_CR138) 2015; 5
D Niewerth (3489_CR146) 2014; 7
C Li (3489_CR118) 2013; 12
A Altmann (3489_CR125) 2012; 53
L Dang (3489_CR135) 2014; 33
TN Moiseeva (3489_CR21) 2013; 44
LR Dick (3489_CR70) 2010; 15
X Yang (3489_CR136) 2012; 66
A Nooka (3489_CR77) 2013; 7
N Rastogi (3489_CR43) 2015; 6
D Chauhan (3489_CR75) 2011; 17
J Fang (3489_CR100) 2012; 120
R Piva (3489_CR72) 2008; 111
H Chen (3489_CR133) 2016; 77
RJ Kaufman (3489_CR32) 2002; 110
AF Baker (3489_CR88) 2014; 33
LM Tseng (3489_CR108) 2012; 14
Z Huang (3489_CR13) 2014; 10
C Huang (3489_CR96) 2007; 3
K Naumann (3489_CR104) 2012; 23
EA Zaal (3489_CR167) 2017; 5
D Chen (3489_CR25) 2011; 11
LH Wilt de (3489_CR29) 2012; 83
D Buac (3489_CR71) 2013; 19
J Voortman (3489_CR87) 2007; 13
DJ Kuhn (3489_CR66) 2007; 110
KR Cron (3489_CR91) 2013; 8
MM Chaturvedi (3489_CR40) 2011; 30
RH Wijdeven (3489_CR1) 2016; 28
JB Almond (3489_CR26) 2002; 16
QP Dou (3489_CR2) 2014; 14
K Rock (3489_CR24) 2002; 80
D Selimovic (3489_CR144) 2013; 25
Y Zhao (3489_CR82) 2015; 10
Y Zang (3489_CR153) 2014; 15
C Li (3489_CR44) 2008; 7
JH Yim (3489_CR123) 2016; 469
Y Vandewynckel (3489_CR130) 2016; 7
R Krȩtowski (3489_CR140) 2014; 389
EA Obeng (3489_CR31) 2006; 107
T Hideshima (3489_CR38) 2009; 114
W Qiang (3489_CR127) 2017; 56
D Ron (3489_CR33) 2002; 110
J Adams (3489_CR19) 2004; 4
MH Glickman (3489_CR20) 2002; 82
C Ceresa (3489_CR89) 2009; 8
S Arastu-Kapur (3489_CR58) 2011; 17
H Chang (3489_CR110) 2014; 5
D Liu (3489_CR134) 2015; 9
H Min (3489_CR101) 2014; 74
F Demarchi (3489_CR16) 2005; 8
SD Demo (3489_CR65) 2007; 67
X Li (3489_CR168) 2010; 102
W Zhu (3489_CR85) 2015; 34
Y-C Lin (3489_CR117) 2012; 48
D Niewerth (3489_CR8) 2015; 18
UB Pandey (3489_CR52) 2007; 447
J Voortman (3489_CR79) 2007; 6
CS Denlinger (3489_CR142) 2014; 13
EE Manasanch (3489_CR27) 2017; 14
M Maynadier (3489_CR116) 2016; 36
J Neukirchen (3489_CR97) 2007; 14
YS Yun (3489_CR160) 2016; 61
References_xml – volume: 77
  start-page: 949
  year: 2016
  end-page: 956
  ident: CR86
  article-title: A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-016-2997-7
– volume: 8
  start-page: 1026
  year: 2009
  end-page: 1037
  ident: CR89
  article-title: Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-0700
– volume: 96
  start-page: 1246
  year: 2011
  end-page: 1248
  ident: CR6
  article-title: Can multiple myeloma become a curable disease?
  publication-title: Haematologica
  doi: 10.3324/haematol.2011.051169
– volume: 20
  start-page: 795
  year: 2014
  end-page: 803
  ident: CR131
  article-title: Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v20.i3.795
– volume: 6
  start-page: 26347
  year: 2015
  end-page: 26358
  ident: CR141
  article-title: IKK Inhibition Increases Bortezomib Effectiveness in Ovarian Cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4713
– volume: 112
  start-page: 659
  year: 2008
  end-page: 670
  ident: CR30
  article-title: Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits
  publication-title: Cancer
  doi: 10.1002/cncr.23224
– volume: 15
  start-page: 243
  year: 2010
  end-page: 249
  ident: CR70
  article-title: Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2010.01.008
– volume: 318
  start-page: 1564
  year: 2012
  end-page: 1576
  ident: CR121
  article-title: The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2012.04.003
– volume: 9
  start-page: 2197
  year: 2012
  end-page: 2205
  ident: CR154
  article-title: Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib
  publication-title: Mol Pharm
  doi: 10.1021/mp300044b
– volume: 43
  start-page: 357
  year: 2014
  end-page: 379
  ident: CR18
  article-title: Structural and functional insights to ubiquitin-like protein conjugation
  publication-title: Annu Rev Biophys
  doi: 10.1146/annurev-biophys-051013-022958
– volume: 121
  start-page: 893
  year: 2013
  end-page: 897
  ident: CR62
  publication-title: Carfilzomib Blood
  doi: 10.1182/blood-2012-10-459883
– volume: 11
  start-page: 254
  year: 2011
  end-page: 284
  ident: CR67
  article-title: Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800911794519716
– volume: 341
  start-page: 174
  year: 2012
  end-page: 182
  ident: CR155
  article-title: Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.111.187542
– volume: 107
  start-page: 4907
  year: 2006
  end-page: 4917
  ident: CR31
  article-title: Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
  publication-title: Blood
  doi: 10.1182/blood-2005-08-3531
– volume: 94
  start-page: 283
  year: 2008
  end-page: 286
  ident: CR51
  article-title: The aggresome pathway as a target for therapy in hematologic malignancies
  publication-title: Mol Genet Metab
  doi: 10.1016/j.ymgme.2008.03.012
– volume: 102
  start-page: 1069
  year: 2010
  end-page: 1082
  ident: CR168
  article-title: Effect of noncompetitive proteasome inhibition on bortezomib resistance
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djq198
– volume: 6
  start-page: 26456
  year: 2016
  ident: CR115
  article-title: Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis
  publication-title: Sci Rep
  doi: 10.1038/srep26456
– volume: 44
  start-page: 1338
  year: 2013
  end-page: 1348
  ident: CR21
  article-title: DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity
  publication-title: Oncotarget
– volume: 103
  start-page: 4952
  year: 2006
  end-page: 4957
  ident: CR103
  article-title: Autophagic programmed cell death by selective catalase degradation
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0511288103
– year: 2017
  ident: CR7
  article-title: (Immuno) proteasomes as therapeutic target in acute leukemia
  publication-title: Cancer Metastasis Rev
– volume: 42
  start-page: 10433
  year: 2014
  end-page: 10447
  ident: CR46
  article-title: MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku763
– volume: 56
  start-page: 73
  year: 1999
  end-page: 82
  ident: CR152
  article-title: Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers
  publication-title: Oncology
  doi: 10.1159/000011933
– volume: 24
  start-page: 218
  year: 2017
  end-page: 230
  ident: CR149
  article-title: Inhibition of the proteasome β2 site sensitizes triple-negative breast cancer cells to β5 inhibitors and suppresses Nrf1 activation
  publication-title: Cell Chem Biol
  doi: 10.1016/j.chembiol.2016.12.016
– volume: 120
  start-page: 947
  year: 2015
  end-page: 960
  ident: CR61
  article-title: Review article Proteasome inhibitors in multiple myeloma: 10 years later
  publication-title: Blood
  doi: 10.1182/blood-2012-04-403733
– volume: 389
  start-page: 177
  year: 2014
  end-page: 185
  ident: CR140
  article-title: Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1939-5
– volume: 7
  start-page: 73697
  year: 2016
  end-page: 73710
  ident: CR114
  article-title: Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells
  publication-title: Oncotarget
– volume: 11
  start-page: 164
  year: 2008
  end-page: 179
  ident: CR39
  article-title: Mechanisms of proteasome inhibitor action and resistance in cancer
  publication-title: Drug Resist
  doi: 10.1016/j.drup.2008.08.002
– volume: 9
  start-page: 1126
  year: 2012
  end-page: 1135
  ident: CR73
  article-title: Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib
  publication-title: Mol Pharm
  doi: 10.1021/mp2004143
– volume: 23
  start-page: 407
  year: 2015
  end-page: 417
  ident: CR9
  article-title: Bortezomib-resistant mutant proteasomes: Structural and biochemical evaluation with carfilzomib and ONX 0914
  publication-title: Structure
  doi: 10.1016/j.str.2014.11.019
– volume: 379
  start-page: 245
  year: 2016
  end-page: 252
  ident: CR129
  article-title: The ubiquitin-proteasome system and its potential application in hepatocellular carcinoma therapy
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.06.023
– volume: 25
  start-page: 292
  year: 2013
  end-page: 297
  ident: CR132
  article-title: Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells
  publication-title: J Chemother
  doi: 10.1179/1973947813Y.0000000087
– volume: 4
  start-page: 349
  year: 2004
  end-page: 360
  ident: CR19
  article-title: The proteasome: a suitable antineoplastic target
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1361
– volume: 26
  start-page: 757
  year: 2012
  end-page: 768
  ident: CR145
  article-title: Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
  publication-title: Leukemia
  doi: 10.1038/leu.2011.256
– volume: 24
  start-page: 5025
  year: 2006
  end-page: 5033
  ident: CR80
  article-title: Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.06.1853
– volume: 6
  start-page: e27996
  year: 2011
  ident: CR148
  article-title: Molecular mechanisms of bortezomib resistant adenocarcinoma cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0027996
– volume: 12
  start-page: 923
  year: 2013
  end-page: 934
  ident: CR118
  article-title: Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest
  publication-title: Cell Cycle
  doi: 10.4161/cc.23882
– volume: 34
  start-page: 471
  year: 2010
  end-page: 474
  ident: CR11
  article-title: Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2009.07.022
– volume: 46
  start-page: 793
  year: 2014
  end-page: 808
  ident: CR22
  article-title: Positioning of aminopeptidase inhibitors in next generation cancer therapy
  publication-title: Amino Acids
  doi: 10.1007/s00726-013-1648-0
– volume: 7
  start-page: 16517
  year: 2016
  end-page: 16528
  ident: CR126
  article-title: Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer
  publication-title: Oncotarget
– ident: CR112
– volume: 129
  start-page: 776
  year: 2005
  end-page: 783
  ident: CR56
  article-title: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2005.05540.x
– volume: 15
  start-page: 781
  year: 2009
  end-page: 787
  ident: CR161
  article-title: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
  publication-title: Nat Med
  doi: 10.1038/nm.1978
– volume: 365
  start-page: 229
  year: 2015
  end-page: 239
  ident: CR99
  article-title: Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.05.025
– volume: 13
  start-page: 81
  year: 2014
  end-page: 86
  ident: CR142
  article-title: A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers
  publication-title: Cancer Res
– volume: 7
  start-page: 1683
  year: 2012
  end-page: 1690
  ident: CR83
  article-title: Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e318267928d
– volume: 99
  start-page: 190
  year: 2002
  end-page: 195
  ident: CR53
  article-title: Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.012485299
– volume: 447
  start-page: 860
  year: 2007
  end-page: 864
  ident: CR52
  article-title: HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS
  publication-title: Nature
  doi: 10.1038/nature05853
– volume: 21
  start-page: 30
  year: 2007
  end-page: 36
  ident: CR41
  article-title: Proteasome inhibitors: antitumor effects and beyond
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404444
– volume: 30
  start-page: 445
  year: 2012
  end-page: 452
  ident: CR5
  article-title: The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.37.8919
– volume: 8
  start-page: 359
  year: 2005
  end-page: 368
  ident: CR16
  article-title: Altering protein turnover in tumor cells: New opportunities for anti-cancer therapies
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2005.12.001
– volume: 111
  start-page: 2765
  year: 2008
  end-page: 2775
  ident: CR72
  article-title: CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
  publication-title: Blood
  doi: 10.1182/blood-2007-07-100651
– volume: 33
  start-page: 111
  year: 2014
  ident: CR88
  article-title: Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-014-0111-8
– volume: 47
  start-page: 56
  year: 2013
  end-page: 62
  ident: CR78
  article-title: Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma
  publication-title: Ann Pharmacother
  doi: 10.1345/aph.1R561
– volume: 25
  start-page: 308
  year: 2013
  end-page: 318
  ident: CR144
  article-title: Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2012.10.004
– volume: 3
  start-page: 83
  year: 2007
  end-page: 93
  ident: CR96
  article-title: Clinical significance of the p53 pathway and associated gene therapy in non-small cell lung cancers
  publication-title: Future Oncol
  doi: 10.2217/14796694.3.1.83
– volume: 10
  start-page: 550
  year: 2009
  end-page: 563
  ident: CR17
  article-title: Breaking the chains: structure and function of the deubiquitinases
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2731
– volume: 79
  start-page: 13
  year: 1994
  end-page: 21
  ident: CR15
  article-title: The ubiquitin-proteasome proteolytic pathway
  publication-title: Cell
  doi: 10.1016/0092-8674(94)90396-4
– volume: 11
  start-page: 239
  year: 2011
  end-page: 253
  ident: CR25
  article-title: Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800911794519752
– volume: 116
  start-page: 4906
  year: 2010
  end-page: 4915
  ident: CR76
  article-title: A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2010-04-276626
– volume: 142
  start-page: 613
  year: 2010
  end-page: 624
  ident: CR159
  article-title: Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress
  publication-title: Cell
  doi: 10.1016/j.cell.2010.07.036
– volume: 80
  start-page: 1
  year: 2002
  end-page: 70
  ident: CR24
  article-title: Protein degradation and the generation of MHC class I-presented peptides
  publication-title: Adv Immunol
  doi: 10.1016/S0065-2776(02)80012-8
– volume: 10
  start-page: 172
  year: 2015
  end-page: 180
  ident: CR82
  article-title: A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000383
– volume: 14
  start-page: R68
  year: 2012
  ident: CR108
  article-title: CIP2A is a target of bortezomib in human triple negative breast cancer cells
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3175
– volume: 17
  start-page: 1636
  year: 2011
  end-page: 1640
  ident: CR169
  article-title: Inhibition of proteasome deubiquitinating activity as a new cancer therapy
  publication-title: Nat Med
  doi: 10.1038/nm.2536
– volume: 49
  start-page: 163
  year: 2005
  end-page: 170
  ident: CR92
  article-title: Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2005.01.006
– volume: 8
  start-page: 3234
  year: 2009
  end-page: 3243
  ident: CR81
  article-title: The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-0239
– volume: 74
  start-page: 167
  year: 2014
  end-page: 176
  ident: CR101
  article-title: Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-014-2451-7
– volume: 33
  start-page: 1083
  year: 2014
  end-page: 1088
  ident: CR135
  article-title: Proteasome inhibitor MG132 inhibits the proliferation and promotes the cisplatin-induced apoptosis of human esophageal squamous cell carcinoma cells
  publication-title: Int J Mol Med
  doi: 10.3892/ijmm.2014.1678
– volume: 34
  start-page: 2083
  year: 2015
  end-page: 2089
  ident: CR85
  article-title: MG132 enhances the radiosensitivity of lung cancer cells in vitro and in vivo
  publication-title: Oncol Rep
  doi: 10.3892/or.2015.4169
– volume: 14
  start-page: 2448
  year: 2010
  end-page: 2459
  ident: CR54
  article-title: Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2009.00832.x
– volume: 30
  start-page: 2303
  year: 2012
  end-page: 2317
  ident: CR106
  article-title: Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-011-9766-6
– volume: 14
  start-page: 431
  year: 2007
  end-page: 439
  ident: CR97
  article-title: The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7701029
– volume: 110
  start-page: 1389
  year: 2002
  end-page: 1398
  ident: CR32
  article-title: Orchestrating the unfolded protein response in health and disease
  publication-title: J Clin Invest
  doi: 10.1172/JCI0216886
– volume: 15
  start-page: 1142
  year: 2014
  end-page: 1152
  ident: CR153
  article-title: Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.29452
– volume: 18
  start-page: 18
  year: 2015
  end-page: 35
  ident: CR8
  article-title: Molecular basis of resistance to proteasome inhibitors in hematological malignancies
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2014.12.001
– volume: 10
  start-page: e0144825
  year: 2015
  ident: CR139
  article-title: KRAS genotype correlates with proteasome inhibitor ixazomib activity in preclinical in vivo models of colon and non-small cell lung cancer: Potential role of tumor metabolism
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0144825
– volume: 33
  start-page: 3696
  year: 2014
  end-page: 3706
  ident: CR165
  article-title: A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis
  publication-title: Oncogene
  doi: 10.1038/onc.2013.336
– volume: 2
  start-page: 215
  year: 1999
  end-page: 223
  ident: CR4
  article-title: Proteasome inhibitors as potential novel anticancer agents
  publication-title: Drug Resist Updat
  doi: 10.1054/drup.1999.0095
– volume: 341
  start-page: 942
  year: 2012
  end-page: 948
  ident: CR120
  article-title: Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma
  publication-title: Head Neck
– volume: 66
  start-page: 607
  year: 2012
  end-page: 611
  ident: CR136
  article-title: Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2012.08.010
– volume: 6
  start-page: 73
  year: 2007
  ident: CR79
  article-title: The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-6-73
– volume: 2
  start-page: 611
  year: 2003
  end-page: 612
  ident: CR37
  article-title: Bortezomib
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd1159
– volume: 19
  start-page: 99
  year: 2012
  end-page: 115
  ident: CR68
  article-title: Proteasome inhibitors: An expanding army attacking a unique target
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2012.01.003
– volume: 9
  start-page: 2278
  year: 2015
  end-page: 2282
  ident: CR134
  article-title: Inhibition of autophagy promotes cell apoptosis induced by the proteasome inhibitor MG-132 in human esophageal squamous cell carcinoma EC9706 cells
  publication-title: Oncol Lett
  doi: 10.3892/ol.2015.3047
– volume: 120
  start-page: 858
  year: 2012
  end-page: 867
  ident: CR100
  article-title: Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1
  publication-title: Blood
  doi: 10.1182/blood-2012-02-407999
– volume: 110
  start-page: 1383
  year: 2002
  end-page: 1388
  ident: CR33
  article-title: Translational control in the endoplasmic reticulum stress response
  publication-title: J Clin Invest
  doi: 10.1172/JCI0216784
– volume: 469
  start-page: 94
  year: 2016
  end-page: 100
  ident: CR123
  article-title: Radiosensitizing effect of PSMC5, a 19S proteasome ATPase, in H460 lung cancer cells
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2015.11.077
– volume: 24
  start-page: 9695
  year: 2004
  end-page: 9704
  ident: CR35
  article-title: Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.24.22.9695-9704.2004
– volume: 52
  start-page: 394
  year: 2011
  end-page: 399
  ident: CR74
  article-title: A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2010.546015
– volume: 9
  start-page: 1004
  year: 2008
  end-page: 1010
  ident: CR102
  article-title: Autophagic cell death: the story of a misnomer
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2529
– volume: 17
  start-page: 5311
  year: 2011
  end-page: 5321
  ident: CR75
  article-title: In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-0476
– volume: 7
  start-page: 1647
  year: 2008
  end-page: 1656
  ident: CR44
  article-title: Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-07-2444
– volume: 173
  start-page: 884
  year: 2016
  end-page: 895
  ident: CR158
  article-title: Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits : application of a novel pharmacodynamic assay
  publication-title: Br J Cancer
– volume: 7
  start-page: 13
  year: 2013
  end-page: 32
  ident: CR77
  article-title: Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
  publication-title: Biol Targets Ther
– volume: 146
  start-page: 619
  year: 2009
  end-page: 626
  ident: CR57
  article-title: Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2009.07803.x
– volume: 7
  start-page: 74779
  year: 2016
  end-page: 74796
  ident: CR163
  article-title: Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11340
– volume: 19
  start-page: 4094
  year: 2013
  end-page: 4114
  ident: CR42
  article-title: Drug combinations with proteasome inhibitors in antitumor therapy
  publication-title: Curr Pharm Des
  doi: 10.2174/1381612811319220015
– volume: 3
  start-page: 13
  year: 2010
  ident: CR166
  article-title: Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-3-13
– volume: 16
  start-page: 433
  year: 2002
  end-page: 443
  ident: CR26
  article-title: The proteasome: a novel target for cancer chemotherapy
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2402417
– volume: 17
  start-page: 2734
  year: 2011
  end-page: 2743
  ident: CR58
  article-title: Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-1950
– volume: 61
  start-page: 625
  year: 2016
  end-page: 639
  ident: CR160
  article-title: mTORC1 coordinates protein synthesis and immunoproteasome formation via PRAS40 to prevent accumulation of protein stress
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2016.01.013
– volume: 13
  start-page: 1075
  year: 2016
  end-page: 1083
  ident: CR107
  article-title: Enhancing the efficiency of bortezomib conjugated to pegylated gold nanoparticles: an in vitro study on human pancreatic cancer cells and adenocarcinoma human lung alveolar basal epithelial cells
  publication-title: Expert Opin Drug Deliv
  doi: 10.1080/17425247.2016.1178234
– volume: 198
  start-page: 577
  year: 2013
  end-page: 582
  ident: CR143
  article-title: The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo
  publication-title: Vet J
  doi: 10.1016/j.tvjl.2013.08.003
– volume: 337
  start-page: 479
  year: 2011
  end-page: 486
  ident: CR69
  article-title: Proteasome regulator marizomib (NPI-0052) exhibits prolonged inhibition, attenuated efflux, and greater cytotoxicity than its reversible analogs
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.110.177824
– volume: 28
  start-page: 65
  year: 2016
  end-page: 81
  ident: CR1
  article-title: Old drugs, novel ways out: drug resistance toward cytotoxic chemotherapeutics
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2016.07.001
– volume: 65
  start-page: 11510
  year: 2005
  end-page: 11520
  ident: CR98
  article-title: Bortezomib Inhibits PKR-Like Endoplasmic Reticulum (ER) Kinase and Induces Apoptosis via ER Stress in Human Pancreatic Cancer Cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2394
– volume: 98
  start-page: 1896
  year: 2013
  end-page: 1904
  ident: CR150
  article-title: Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.092411
– volume: 8
  start-page: e73710
  year: 2013
  ident: CR91
  article-title: Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0073710
– volume: 5
  start-page: e1540
  year: 2014
  ident: CR110
  article-title: Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2014.504
– volume: 291
  start-page: 18199
  year: 2016
  end-page: 18209
  ident: CR122
  article-title: Inhibition of HDAC6 protein enhances bortezomib-induced apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by reducing autophagy
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M116.717793
– volume: 98
  start-page: 217
  year: 2013
  end-page: 226
  ident: CR128
  article-title: Beclin 1 enhances proteasome inhibition-mediated cytotoxicity of thyroid cancer cells in macroautophagy-independent manner
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2012-2679
– volume: 55
  start-page: 4199
  year: 2016
  end-page: 4203
  ident: CR157
  article-title: A set of activity-based probes to visualize human (immuno) proteasome activities
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.201509092
– volume: 56
  start-page: 98
  year: 2017
  end-page: 108
  ident: CR127
  article-title: Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a
  publication-title: Endocrine
  doi: 10.1007/s12020-017-1256-y
– volume: 48
  start-page: 585
  year: 2012
  end-page: 593
  ident: CR117
  article-title: CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2012.01.012
– volume: 11
  start-page: 2317
  year: 2009
  end-page: 2331
  ident: CR34
  article-title: Oxidative folding: cellular strategies for dealing with the resultant equimolar production of reactive oxygen species
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2009.2501
– volume: 53
  start-page: 1764
  year: 2012
  end-page: 1771
  ident: CR125
  article-title: Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.111.101295
– volume: 89
  start-page: 43
  year: 2014
  end-page: 51
  ident: CR147
  article-title: Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2014.02.005
– volume: 73
  start-page: 69
  year: 2014
  end-page: 77
  ident: CR105
  article-title: Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-013-2318-3
– volume: 6
  start-page: 43310
  year: 2015
  end-page: 43325
  ident: CR43
  article-title: Proteasome inhibition mediates p53 reactivation and anti- cancer activity of 6-Gingerol in cervical cancer cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6383
– volume: 5
  start-page: e1580
  year: 2014
  ident: CR111
  article-title: Suppression of BRCA1 sensitizes cells to proteasome inhibitors
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2014.537
– volume: 98
  start-page: 1753
  year: 2013
  end-page: 1761
  ident: CR63
  article-title: Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.089334
– volume: 110
  start-page: 3281
  year: 2007
  end-page: 3290
  ident: CR66
  article-title: Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2007-01-065888
– volume: 49
  start-page: 1848
  year: 2016
  end-page: 1858
  ident: CR113
  article-title: Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2016.3673
– volume: 15
  start-page: R108
  year: 2013
  end-page: R108
  ident: CR109
  article-title: Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3575
– volume: 1810
  start-page: 1110
  year: 2011
  end-page: 1113
  ident: CR164
  article-title: Regulation of mucin secretion and inflammation in asthma: a role for MARCKS protein?
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbagen.2011.01.009
– volume: 7
  start-page: 227
  year: 2005
  end-page: 238
  ident: CR45
  article-title: Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.02.008
– volume: 82
  start-page: 373
  year: 2002
  end-page: 428
  ident: CR20
  article-title: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00027.2001
– volume: 1
  start-page: 3773
  year: 2006
  end-page: 3782
  ident: CR50
  article-title: Aggresome disruption: a novel strategy to enhance bortezomib- induced apoptosis in pancreatic cancer cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2961
– volume: 35
  start-page: 316
  year: 2014
  end-page: 326
  ident: CR93
  article-title: The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.09.098
– volume: 282
  start-page: 4702
  year: 2007
  end-page: 4710
  ident: CR49
  article-title: Differential effects of endoplasmic reticulum stress-induced autophagy on cell survival
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M609267200
– volume: 27
  start-page: 1189
  year: 2008
  end-page: 1197
  ident: CR47
  article-title: BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210744
– volume: 171
  start-page: 513
  year: 2007
  end-page: 524
  ident: CR48
  article-title: Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2007.070188
– volume: 10
  start-page: e0141681
  year: 2015
  ident: CR137
  article-title: Inhibition on proteasome B1 subunit might contribute to the anti-cancer effects of fangchinoline in human prostate cancer cells
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0141681
– volume: 355
  start-page: 168
  year: 2015
  end-page: 173
  ident: CR94
  article-title: Polymer micelle formulations of proteasome inhibitor farfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and ung cancer cell lines
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.115.226993
– volume: 103
  start-page: 1007
  year: 2011
  end-page: 1017
  ident: CR64
  article-title: Novel proteasome inhibitors to overcome bortezomib resistance
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr160
– volume: 22
  start-page: 319
  year: 2015
  end-page: 329
  ident: CR124
  article-title: Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer
  publication-title: Endocr Relat Cancer
  doi: 10.1530/ERC-14-0510
– volume: 30
  start-page: 1615
  year: 2011
  end-page: 1630
  ident: CR40
  article-title: NFkB addiction and its role in cancer : “one size does not fit all
  publication-title: ” Oncogene
  doi: 10.1038/onc.2010.566
– volume: 7
  start-page: 215
  year: 1995
  end-page: 223
  ident: CR3
  article-title: Ubiquitin, proteasomes, and the regulation of intracellular protein degradation
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/0955-0674(95)80031-X
– volume: 5
  start-page: 7
  year: 2017
  ident: CR167
  article-title: Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
  publication-title: Cancer Metab
  doi: 10.1186/s40170-017-0169-9
– volume: 7
  start-page: 34988
  year: 2016
  end-page: 35000
  ident: CR130
  article-title: Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9222
– volume: 10
  start-page: 73
  year: 2010
  end-page: 78
  ident: CR28
  article-title: Proteasomes in immune cells: more than peptide producers?
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2687
– volume: 13
  start-page: 3642
  year: 2007
  end-page: 3652
  ident: CR87
  article-title: A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-0061
– volume: 104
  start-page: 19512
  year: 2007
  end-page: 19517
  ident: CR151
  article-title: Small molecule obatoclax (GX15–070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.0709443104
– volume: 107
  start-page: 257
  year: 2006
  end-page: 264
  ident: CR36
  article-title: The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status
  publication-title: Blood
  doi: 10.1182/blood-2005-05-2091
– volume: 85
  start-page: 363
  year: 2013
  end-page: 372
  ident: CR90
  article-title: Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells?
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2012.08.001
– volume: 112
  start-page: 2489
  year: 2008
  end-page: 2499
  ident: CR156
  article-title: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein
  publication-title: Blood
  doi: 10.1182/blood-2007-08-104950
– volume: 7
  start-page: 7
  year: 2014
  ident: CR146
  article-title: Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-7-7
– volume: 51
  start-page: 1178
  year: 2010
  end-page: 1187
  ident: CR12
  article-title: Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2010.483303
– volume: 86
  start-page: 12
  year: 2014
  end-page: 19
  ident: CR10
  article-title: Antileukemic activity and mechanism of drug resistance to the marine proteasome inhibitor salinosporamide A (Marizomib)
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.114.092114
– volume: 67
  start-page: 6383
  year: 2007
  end-page: 6391
  ident: CR65
  article-title: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-4086
– volume: 104
  start-page: 273
  year: 2016
  end-page: 280
  ident: CR14
  article-title: Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma
  publication-title: Int J Hematol
  doi: 10.1007/s12185-016-2016-0
– volume: 19
  start-page: 4025
  year: 2013
  end-page: 4038
  ident: CR71
  article-title: From bortezomib to other inhibitors of the proteasome and beyond
  publication-title: Curr Pharm Des
  doi: 10.2174/1381612811319220012
– volume: 35
  start-page: 608
  year: 2017
  end-page: 615
  ident: CR84
  article-title: Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-017-0441-4
– volume: 18
  start-page: 5639
  year: 2012
  end-page: 5649
  ident: CR119
  article-title: Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-1213
– volume: 10
  start-page: 1795
  year: 2014
  end-page: 1807
  ident: CR13
  article-title: Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials
  publication-title: Future Oncol
  doi: 10.2217/fon.14.30
– volume: 14
  start-page: 517
  year: 2014
  end-page: 536
  ident: CR2
  article-title: Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/1568009614666140804154511
– volume: 83
  start-page: 207
  year: 2012
  end-page: 217
  ident: CR29
  article-title: Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2011.10.009
– volume: 28
  start-page: 4621
  year: 2010
  end-page: 4629
  ident: CR55
  article-title: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005–01 phase III trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.9158
– volume: 77
  start-page: 108
  year: 2016
  end-page: 113
  ident: CR133
  article-title: The molecular mechanisms of XBP-1 gene silencing on IRE1α-TRAF2-ASK1-JNK pathways in oral squamous cell carcinoma under endoplasmic reticulum stress
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2015.12.010
– volume: 114
  start-page: 1046
  year: 2009
  end-page: 1052
  ident: CR38
  article-title: Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
  publication-title: Blood
  doi: 10.1182/blood-2009-01-199604
– volume: 18
  start-page: 97
  year: 2003
  end-page: 108
  ident: CR23
  article-title: Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I
  publication-title: Immunity
  doi: 10.1016/S1074-7613(02)00511-3
– volume: 36
  start-page: 1127
  year: 2016
  end-page: 1134
  ident: CR116
  article-title: Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.4873
– volume: 14
  start-page: 417
  year: 2017
  end-page: 433
  ident: CR27
  article-title: Proteasome inhibitors in cancer therapy
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2016.206
– ident: CR59
– volume: 5
  start-page: 77
  year: 2017
  end-page: 88
  ident: CR95
  article-title: Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment
  publication-title: Biomater Sci
  doi: 10.1039/C6BM00449K
– volume: 23
  start-page: 614
  year: 2012
  end-page: 626
  ident: CR104
  article-title: Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0b013e3283504e53
– volume: 38
  start-page: 1
  year: 2014
  end-page: 9
  ident: CR60
  article-title: New orally active proteasome inhibitors in multiple myeloma
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2013.10.018
– volume: 5
  start-page: 15270
  year: 2015
  ident: CR138
  article-title: EGCG antagonizes Bortezomib cytotoxicity in prostate cancer cells by an autophagic mechanism
  publication-title: Sci Rep
  doi: 10.1038/srep15270
– volume: 5
  start-page: e1067
  year: 2014
  ident: CR162
  article-title: Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2014.39
– volume: 15
  start-page: R108
  year: 2013
  ident: 3489_CR109
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3575
– volume: 8
  start-page: e73710
  year: 2013
  ident: 3489_CR91
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0073710
– volume: 7
  start-page: 13
  year: 2013
  ident: 3489_CR77
  publication-title: Biol Targets Ther
  doi: 10.2147/BTT.S24580
– volume: 110
  start-page: 1389
  year: 2002
  ident: 3489_CR32
  publication-title: J Clin Invest
  doi: 10.1172/JCI200216886
– volume: 14
  start-page: 2448
  year: 2010
  ident: 3489_CR54
  publication-title: J Cell Mol Med
  doi: 10.1111/j.1582-4934.2009.00832.x
– volume: 99
  start-page: 190
  year: 2002
  ident: 3489_CR53
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.012485299
– volume: 142
  start-page: 613
  year: 2010
  ident: 3489_CR159
  publication-title: Cell
  doi: 10.1016/j.cell.2010.07.036
– volume: 103
  start-page: 4952
  year: 2006
  ident: 3489_CR103
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0511288103
– volume: 173
  start-page: 884
  year: 2016
  ident: 3489_CR158
  publication-title: Br J Cancer
  doi: 10.1111/bjh.14014
– volume: 282
  start-page: 4702
  year: 2007
  ident: 3489_CR49
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M609267200
– volume: 23
  start-page: 407
  year: 2015
  ident: 3489_CR9
  publication-title: Structure
  doi: 10.1016/j.str.2014.11.019
– volume: 53
  start-page: 1764
  year: 2012
  ident: 3489_CR125
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.111.101295
– volume: 21
  start-page: 30
  year: 2007
  ident: 3489_CR41
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2404444
– volume: 23
  start-page: 614
  year: 2012
  ident: 3489_CR104
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0b013e3283504e53
– volume: 7
  start-page: 7
  year: 2014
  ident: 3489_CR146
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-7-7
– volume: 30
  start-page: 445
  year: 2012
  ident: 3489_CR5
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.37.8919
– volume: 198
  start-page: 577
  year: 2013
  ident: 3489_CR143
  publication-title: Vet J
  doi: 10.1016/j.tvjl.2013.08.003
– volume: 98
  start-page: 1753
  year: 2013
  ident: 3489_CR63
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.089334
– volume: 18
  start-page: 97
  year: 2003
  ident: 3489_CR23
  publication-title: Immunity
  doi: 10.1016/S1074-7613(02)00511-3
– volume: 103
  start-page: 1007
  year: 2011
  ident: 3489_CR64
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djr160
– volume: 22
  start-page: 319
  year: 2015
  ident: 3489_CR124
  publication-title: Endocr Relat Cancer
  doi: 10.1530/ERC-14-0510
– volume: 96
  start-page: 1246
  year: 2011
  ident: 3489_CR6
  publication-title: Haematologica
  doi: 10.3324/haematol.2011.051169
– volume: 7
  start-page: 227
  year: 2005
  ident: 3489_CR45
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.02.008
– volume: 24
  start-page: 5025
  year: 2006
  ident: 3489_CR80
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.06.1853
– volume: 44
  start-page: 1338
  year: 2013
  ident: 3489_CR21
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.1060
– volume: 42
  start-page: 10433
  year: 2014
  ident: 3489_CR46
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku763
– volume: 38
  start-page: 1
  year: 2014
  ident: 3489_CR60
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2013.10.018
– volume: 25
  start-page: 308
  year: 2013
  ident: 3489_CR144
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2012.10.004
– volume: 6
  start-page: 26456
  year: 2016
  ident: 3489_CR115
  publication-title: Sci Rep
  doi: 10.1038/srep26456
– volume: 34
  start-page: 471
  year: 2010
  ident: 3489_CR11
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2009.07.022
– volume: 355
  start-page: 168
  year: 2015
  ident: 3489_CR94
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.115.226993
– volume: 98
  start-page: 217
  year: 2013
  ident: 3489_CR128
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2012-2679
– volume: 17
  start-page: 2734
  year: 2011
  ident: 3489_CR58
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-10-1950
– volume: 10
  start-page: 73
  year: 2010
  ident: 3489_CR28
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2687
– volume: 104
  start-page: 273
  year: 2016
  ident: 3489_CR14
  publication-title: Int J Hematol
  doi: 10.1007/s12185-016-2016-0
– volume: 48
  start-page: 585
  year: 2012
  ident: 3489_CR117
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2012.01.012
– volume: 107
  start-page: 4907
  year: 2006
  ident: 3489_CR31
  publication-title: Blood
  doi: 10.1182/blood-2005-08-3531
– volume: 79
  start-page: 13
  year: 1994
  ident: 3489_CR15
  publication-title: Cell
  doi: 10.1016/0092-8674(94)90396-4
– volume: 107
  start-page: 257
  year: 2006
  ident: 3489_CR36
  publication-title: Blood
  doi: 10.1182/blood-2005-05-2091
– volume: 114
  start-page: 1046
  year: 2009
  ident: 3489_CR38
  publication-title: Blood
  doi: 10.1182/blood-2009-01-199604
– volume: 5
  start-page: 77
  year: 2017
  ident: 3489_CR95
  publication-title: Biomater Sci
  doi: 10.1039/C6BM00449K
– ident: 3489_CR112
  doi: 10.3892/ijo.2011.1317
– volume: 341
  start-page: 174
  year: 2012
  ident: 3489_CR155
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.111.187542
– volume: 3
  start-page: 13
  year: 2010
  ident: 3489_CR166
  publication-title: J Hematol Oncol
  doi: 10.1186/1756-8722-3-13
– volume: 51
  start-page: 1178
  year: 2010
  ident: 3489_CR12
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2010.483303
– volume: 104
  start-page: 19512
  year: 2007
  ident: 3489_CR151
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.0709443104
– volume: 16
  start-page: 433
  year: 2002
  ident: 3489_CR26
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2402417
– volume: 116
  start-page: 4906
  year: 2010
  ident: 3489_CR76
  publication-title: Blood
  doi: 10.1182/blood-2010-04-276626
– volume: 80
  start-page: 1
  year: 2002
  ident: 3489_CR24
  publication-title: Adv Immunol
  doi: 10.1016/S0065-2776(02)80012-8
– ident: 3489_CR59
– volume: 365
  start-page: 229
  year: 2015
  ident: 3489_CR99
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.05.025
– volume: 19
  start-page: 4094
  year: 2013
  ident: 3489_CR42
  publication-title: Curr Pharm Des
  doi: 10.2174/1381612811319220015
– volume: 13
  start-page: 81
  year: 2014
  ident: 3489_CR142
  publication-title: Cancer Res
  doi: 10.1016/j.clcc.2013.12.005
– volume: 30
  start-page: 1615
  year: 2011
  ident: 3489_CR40
  publication-title: ” Oncogene
  doi: 10.1038/onc.2010.566
– volume: 6
  start-page: 43310
  year: 2015
  ident: 3489_CR43
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6383
– volume: 112
  start-page: 659
  year: 2008
  ident: 3489_CR30
  publication-title: Cancer
  doi: 10.1002/cncr.23224
– volume: 171
  start-page: 513
  year: 2007
  ident: 3489_CR48
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2007.070188
– volume: 121
  start-page: 893
  year: 2013
  ident: 3489_CR62
  publication-title: Carfilzomib Blood
  doi: 10.1182/blood-2012-10-459883
– volume: 6
  start-page: 26347
  year: 2015
  ident: 3489_CR141
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4613
– volume: 18
  start-page: 5639
  year: 2012
  ident: 3489_CR119
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-1213
– volume: 77
  start-page: 949
  year: 2016
  ident: 3489_CR86
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-016-2997-7
– volume: 5
  start-page: e1540
  year: 2014
  ident: 3489_CR110
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2014.504
– volume: 46
  start-page: 793
  year: 2014
  ident: 3489_CR22
  publication-title: Amino Acids
  doi: 10.1007/s00726-013-1648-0
– volume: 111
  start-page: 2765
  year: 2008
  ident: 3489_CR72
  publication-title: Blood
  doi: 10.1182/blood-2007-07-100651
– volume: 146
  start-page: 619
  year: 2009
  ident: 3489_CR57
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2009.07803.x
– volume: 1
  start-page: 3773
  year: 2006
  ident: 3489_CR50
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2961
– volume: 14
  start-page: R68
  year: 2012
  ident: 3489_CR108
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3175
– volume: 18
  start-page: 18
  year: 2015
  ident: 3489_CR8
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2014.12.001
– volume: 7
  start-page: 1683
  year: 2012
  ident: 3489_CR83
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0b013e318267928d
– volume: 24
  start-page: 218
  year: 2017
  ident: 3489_CR149
  publication-title: Cell Chem Biol
  doi: 10.1016/j.chembiol.2016.12.016
– volume: 10
  start-page: 1795
  year: 2014
  ident: 3489_CR13
  publication-title: Future Oncol
  doi: 10.2217/fon.14.30
– volume: 7
  start-page: 1647
  year: 2008
  ident: 3489_CR44
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-07-2444
– volume: 379
  start-page: 245
  year: 2016
  ident: 3489_CR129
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2015.06.023
– volume: 13
  start-page: 3642
  year: 2007
  ident: 3489_CR87
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-0061
– volume: 17
  start-page: 5311
  year: 2011
  ident: 3489_CR75
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-0476
– volume: 10
  start-page: 550
  year: 2009
  ident: 3489_CR17
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2731
– volume: 8
  start-page: 3234
  year: 2009
  ident: 3489_CR81
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-09-0239
– volume: 26
  start-page: 757
  year: 2012
  ident: 3489_CR145
  publication-title: Leukemia
  doi: 10.1038/leu.2011.256
– volume: 33
  start-page: 3696
  year: 2014
  ident: 3489_CR165
  publication-title: Oncogene
  doi: 10.1038/onc.2013.336
– volume: 112
  start-page: 2489
  year: 2008
  ident: 3489_CR156
  publication-title: Blood
  doi: 10.1182/blood-2007-08-104950
– volume: 15
  start-page: 1142
  year: 2014
  ident: 3489_CR153
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.29452
– volume: 52
  start-page: 394
  year: 2011
  ident: 3489_CR74
  publication-title: Leuk Lymphoma
  doi: 10.3109/10428194.2010.546015
– volume: 35
  start-page: 316
  year: 2014
  ident: 3489_CR93
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.09.098
– volume: 49
  start-page: 1848
  year: 2016
  ident: 3489_CR113
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2016.3673
– volume: 28
  start-page: 65
  year: 2016
  ident: 3489_CR1
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2016.07.001
– volume: 2
  start-page: 215
  year: 1999
  ident: 3489_CR4
  publication-title: Drug Resist Updat
  doi: 10.1054/drup.1999.0095
– volume: 74
  start-page: 167
  year: 2014
  ident: 3489_CR101
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-014-2451-7
– volume: 11
  start-page: 164
  year: 2008
  ident: 3489_CR39
  publication-title: Drug Resist
  doi: 10.1016/j.drup.2008.08.002
– volume: 67
  start-page: 6383
  year: 2007
  ident: 3489_CR65
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-4086
– volume: 9
  start-page: 1126
  year: 2012
  ident: 3489_CR73
  publication-title: Mol Pharm
  doi: 10.1021/mp2004143
– volume: 33
  start-page: 111
  year: 2014
  ident: 3489_CR88
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-014-0111-8
– volume: 7
  start-page: 16517
  year: 2016
  ident: 3489_CR126
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7760
– year: 2017
  ident: 3489_CR7
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-017-9699-4
– volume: 86
  start-page: 12
  year: 2014
  ident: 3489_CR10
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.114.092114
– volume: 8
  start-page: 359
  year: 2005
  ident: 3489_CR16
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2005.12.001
– volume: 94
  start-page: 283
  year: 2008
  ident: 3489_CR51
  publication-title: Mol Genet Metab
  doi: 10.1016/j.ymgme.2008.03.012
– volume: 12
  start-page: 923
  year: 2013
  ident: 3489_CR118
  publication-title: Cell Cycle
  doi: 10.4161/cc.23882
– volume: 2
  start-page: 611
  year: 2003
  ident: 3489_CR37
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd1159
– volume: 10
  start-page: e0144825
  year: 2015
  ident: 3489_CR139
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0144825
– volume: 9
  start-page: 2197
  year: 2012
  ident: 3489_CR154
  publication-title: Mol Pharm
  doi: 10.1021/mp300044b
– volume: 129
  start-page: 776
  year: 2005
  ident: 3489_CR56
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2005.05540.x
– volume: 389
  start-page: 177
  year: 2014
  ident: 3489_CR140
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1939-5
– volume: 110
  start-page: 3281
  year: 2007
  ident: 3489_CR66
  publication-title: Blood
  doi: 10.1182/blood-2007-01-065888
– volume: 36
  start-page: 1127
  year: 2016
  ident: 3489_CR116
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.4873
– volume: 19
  start-page: 4025
  year: 2013
  ident: 3489_CR71
  publication-title: Curr Pharm Des
  doi: 10.2174/1381612811319220012
– volume: 7
  start-page: 74779
  year: 2016
  ident: 3489_CR163
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11340
– volume: 82
  start-page: 373
  year: 2002
  ident: 3489_CR20
  publication-title: Physiol Rev
  doi: 10.1152/physrev.00027.2001
– volume: 14
  start-page: 417
  year: 2017
  ident: 3489_CR27
  publication-title: Nat Rev Clin Oncol
  doi: 10.1007/s12079-011-0121-7
– volume: 11
  start-page: 254
  year: 2011
  ident: 3489_CR67
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800911794519716
– volume: 11
  start-page: 2317
  year: 2009
  ident: 3489_CR34
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2009.2501
– volume: 14
  start-page: 517
  year: 2014
  ident: 3489_CR2
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/1568009614666140804154511
– volume: 7
  start-page: 215
  year: 1995
  ident: 3489_CR3
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/0955-0674(95)80031-X
– volume: 6
  start-page: 73
  year: 2007
  ident: 3489_CR79
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-6-73
– volume: 89
  start-page: 43
  year: 2014
  ident: 3489_CR147
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2014.02.005
– volume: 4
  start-page: 349
  year: 2004
  ident: 3489_CR19
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1361
– volume: 120
  start-page: 858
  year: 2012
  ident: 3489_CR100
  publication-title: Blood
  doi: 10.1182/blood-2012-02-407999.The
– volume: 110
  start-page: 1383
  year: 2002
  ident: 3489_CR33
  publication-title: J Clin Invest
  doi: 10.1172/JCI200216784
– volume: 24
  start-page: 9695
  year: 2004
  ident: 3489_CR35
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.24.22.9695
– volume: 291
  start-page: 18199
  year: 2016
  ident: 3489_CR122
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M116.717793
– volume: 27
  start-page: 1189
  year: 2008
  ident: 3489_CR47
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210744
– volume: 3
  start-page: 83
  year: 2007
  ident: 3489_CR96
  publication-title: Future Oncol
  doi: 10.2217/14796694.3.1.83
– volume: 9
  start-page: 1004
  year: 2008
  ident: 3489_CR102
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm2529
– volume: 28
  start-page: 4621
  year: 2010
  ident: 3489_CR55
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.27.9158
– volume: 9
  start-page: 2278
  year: 2015
  ident: 3489_CR134
  publication-title: Oncol Lett
  doi: 10.3892/ol.2015.3047
– volume: 34
  start-page: 2083
  year: 2015
  ident: 3489_CR85
  publication-title: Oncol Rep
  doi: 10.3892/or.2015.4169
– volume: 6
  start-page: e27996
  year: 2011
  ident: 3489_CR148
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0027996
– volume: 5
  start-page: e1067
  year: 2014
  ident: 3489_CR162
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2014.39
– volume: 47
  start-page: 56
  year: 2013
  ident: 3489_CR78
  publication-title: Ann Pharmacother
  doi: 10.1345/aph.1R561
– volume: 5
  start-page: 7
  year: 2017
  ident: 3489_CR167
  publication-title: Cancer Metab
  doi: 10.1186/s40170-017-0169-9
– volume: 55
  start-page: 4199
  year: 2016
  ident: 3489_CR157
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.201509092
– volume: 43
  start-page: 357
  year: 2014
  ident: 3489_CR18
  publication-title: Annu Rev Biophys
  doi: 10.1146/annurev-biophys-051013-022958
– volume: 5
  start-page: 15270
  year: 2015
  ident: 3489_CR138
  publication-title: Sci Rep
  doi: 10.1038/srep15270
– volume: 56
  start-page: 73
  year: 1999
  ident: 3489_CR152
  publication-title: Oncology
  doi: 10.1159/000011933
– volume: 341
  start-page: 942
  year: 2012
  ident: 3489_CR120
  publication-title: Head Neck
  doi: 10.1002/HED
– volume: 25
  start-page: 292
  year: 2013
  ident: 3489_CR132
  publication-title: J Chemother
  doi: 10.1179/1973947813Y.0000000087
– volume: 17
  start-page: 1636
  year: 2011
  ident: 3489_CR169
  publication-title: Nat Med
  doi: 10.1038/nm.2536
– volume: 120
  start-page: 947
  year: 2015
  ident: 3489_CR61
  publication-title: Blood
  doi: 10.1182/blood-2012-04-403733
– volume: 30
  start-page: 2303
  year: 2012
  ident: 3489_CR106
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-011-9766-6
– volume: 13
  start-page: 1075
  year: 2016
  ident: 3489_CR107
  publication-title: Expert Opin Drug Deliv
  doi: 10.1080/17425247.2016.1178234
– volume: 33
  start-page: 1083
  year: 2014
  ident: 3489_CR135
  publication-title: Int J Mol Med
  doi: 10.3892/ijmm.2014.1678
– volume: 65
  start-page: 11510
  year: 2005
  ident: 3489_CR98
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-2394
– volume: 14
  start-page: 431
  year: 2007
  ident: 3489_CR97
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7701029
– volume: 56
  start-page: 98
  year: 2017
  ident: 3489_CR127
  publication-title: Endocrine
  doi: 10.1007/s12020-017-1256-y
– volume: 66
  start-page: 607
  year: 2012
  ident: 3489_CR136
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2012.08.010
– volume: 337
  start-page: 479
  year: 2011
  ident: 3489_CR69
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.110.177824.is
– volume: 15
  start-page: 781
  year: 2009
  ident: 3489_CR161
  publication-title: Nat Med
  doi: 10.1038/nm.1978
– volume: 85
  start-page: 363
  year: 2013
  ident: 3489_CR90
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2012.08.001
– volume: 7
  start-page: 34988
  year: 2016
  ident: 3489_CR130
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9222
– volume: 20
  start-page: 795
  year: 2014
  ident: 3489_CR131
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v20.i3.795
– volume: 83
  start-page: 207
  year: 2012
  ident: 3489_CR29
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2011.10.009
– volume: 61
  start-page: 625
  year: 2016
  ident: 3489_CR160
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2016.01.013
– volume: 73
  start-page: 69
  year: 2014
  ident: 3489_CR105
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-013-2318-3
– volume: 318
  start-page: 1564
  year: 2012
  ident: 3489_CR121
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2012.04.003
– volume: 35
  start-page: 608
  year: 2017
  ident: 3489_CR84
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-017-0441-4
– volume: 15
  start-page: 243
  year: 2010
  ident: 3489_CR70
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2010.01.008
– volume: 77
  start-page: 108
  year: 2016
  ident: 3489_CR133
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2015.12.010
– volume: 10
  start-page: e0141681
  year: 2015
  ident: 3489_CR137
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0141681
– volume: 10
  start-page: 172
  year: 2015
  ident: 3489_CR82
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000383
– volume: 98
  start-page: 1896
  year: 2013
  ident: 3489_CR150
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.092411
– volume: 7
  start-page: 73697
  year: 2016
  ident: 3489_CR114
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12048
– volume: 8
  start-page: 1026
  year: 2009
  ident: 3489_CR89
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-08-0700
– volume: 1810
  start-page: 1110
  year: 2011
  ident: 3489_CR164
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbagen.2011.01.009
– volume: 447
  start-page: 860
  year: 2007
  ident: 3489_CR52
  publication-title: Nature
  doi: 10.1038/nature05853
– volume: 102
  start-page: 1069
  year: 2010
  ident: 3489_CR168
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djq198
– volume: 49
  start-page: 163
  year: 2005
  ident: 3489_CR92
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2005.01.006
– volume: 11
  start-page: 239
  year: 2011
  ident: 3489_CR25
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800911794519752
– volume: 19
  start-page: 99
  year: 2012
  ident: 3489_CR68
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2012.01.003
– volume: 5
  start-page: e1580
  year: 2014
  ident: 3489_CR111
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2014.537
– volume: 469
  start-page: 94
  year: 2016
  ident: 3489_CR123
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2015.11.077
SSID ssj0004133
Score 2.5405061
SecondaryResourceType review_article
Snippet Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 227
SubjectTerms Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer
Cancer Research
Colon
Cytotoxic Reviews
Drug Resistance, Neoplasm
Head & neck cancer
Humans
Medicine
Medicine & Public Health
Molecular modelling
Neoplasms - drug therapy
Oncology
Pancreas
Pharmacology/Toxicology
Protease inhibitors
Proteasome Endopeptidase Complex - chemistry
Proteasome Endopeptidase Complex - drug effects
Proteasome inhibitors
Proteasome Inhibitors - pharmacology
Proteasome Inhibitors - therapeutic use
Proteasomes
Review
Review Article
Solid tumors
Targeted cancer therapy
Ubiquitin
SummonAdditionalLinks – databaseName: SpringerLINK Contemporary 1997-Present
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swED5tbJp4YazbWDaYjDT1YcOSnTi1_TghEA-AKuimvkV27IxIkCJSJvW_x3Z-lMKYtL1F8iVO7Dv7c-7uO4AvImU0N4xiQ7nFjGmJtVYEFzK2uZKy0EWY6WN-eiqmUzlu87jrLtq9c0mGlbpPdgteQOxX1YT5OJ_n8MLtdsJb49n5z2UyJG3qxyeM4ZQT1rky__SI1c3oEcJ8HCj5wFsaNqHD1__1-puw0WJO9L1RkjfwzFYDeHXSetUHMBw3_NWLPTRZpmPVe2iIxktm68VbOBi3IV6uYzQrUCB5UPXsyqKyuih16Uv3uEvUZHUtvIzT7dKgKwf3fzWVgOt38OPwYLJ_hNs6DDhPk9EcF7FORcjhVYRoaYxQDjVJwUXOR7RQDuEQqxLrkJcwRFFWWHfoM5QZrlKWjJL3sFbNKvsBECdqZITQnOUps5pIFTMu_G8o70_M4whINyFZ3pKU-1oZl1lPrxzGMXPjmPlxzEgEX_tbrhuGjr8Jb3eznLXGWmeeIcjh0pSzCHb7Zmdm3neiKju79TLcHeBpzEUEW41S9L3F0h2TJacR8BV16QU8hfdqS1VeBCrvlHPheo7gW6c0917rqY_4-E_Sn2DdgTzRRJpvw9r85tbuwMv897ysbz4H27kD_zgTDQ
  priority: 102
  providerName: Springer Nature
Title Positioning of proteasome inhibitors in therapy of solid malignancies
URI https://link.springer.com/article/10.1007/s00280-017-3489-0
https://www.ncbi.nlm.nih.gov/pubmed/29184971
https://www.proquest.com/docview/1969416574
https://www.proquest.com/docview/1970271278
https://pubmed.ncbi.nlm.nih.gov/PMC5778165
Volume 81
WOSCitedRecordID wos000423112600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1432-0843
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0004133
  issn: 0344-5704
  databaseCode: RSV
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFiEuFMorUFZGQj1ArTpZZ22fqrbaigOsolLQ3iK_QiPRpDRbpP332M5jWSp64RIl8kS2NTP2jGf8DcA7ntJYGxpjEzOLKVUCKyUJLkRitRSiUEXg9Cc2m_H5XGTdgVvTpVX2a2JYqE2t_Rn5gYdxccZDyujh1U_sq0b56GpXQmMDtuKEUK-Y_GSV4uEW6LY8MqU4ZYT2UU0SQEQT7lOynIpRnzW0vi_dMjZv50z-FTgN-9Hp9v_O5DE86ixRdNSKzhO4Z6sdePC5i7XvwF7Wolov99H56pJWs4_2ULbCu14-hWnWJX65caK6QAH6QTb1pUVldVGq0hf0ca-oveu19DRO4kuDLp0T8L2tD9w8g6-n0_OTj7irzoB1Op4scJGolIebvZIQJYzh0tlSgjOu2SQupLN7iJVj6-wxboiMaWGdK2hiaphM6Xgyfg6bVV3Zl4AYkRPDuWJUp9QqImRCGfeHUz7KqJMISM-bXHfQ5b6Cxo98AF0O7MwdO3PPzpxE8H745arF7biLeLfnVN6pcJOv2BTB26HZKZ-PqMjK1jeehjm3Pk4Yj-BFKx9Db4lwzrNgcQRsTXIGAg_svd5SlRcB4DtljLueI_jQy9gfw_rXJF7dPYnX8NDZerxNON-FzcX1jX0D9_WvRdlcj2CDzVl48lHQoRFsHU9n2Zn7Ovvy7Tdp7iH6
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB2VgqAXPkqhgQJGgh5oIxzHWTsHhBC0atXtag-LtLfgxA6NRJPSbEH7p_iNjOMky1LRWw_cItmJ4-R5POOZeQPwSkY8yDQPfB0I43Oexn6aKurnMTOZiuM8zZs_PRSjkZxO4_EK_OpyYWxYZScTG0Gtq8yekb-1NC6oPESCvz_77tuqUda72pXQcLA4MvOfaLLV7w4_4f99zdj-3uTjgd9WFfCzKBzM_JylkWwyUhWlaay1VKgDoOktMzTpc4X7NTUqNKhHSE1VwHODJowOuBYq4uEgxOfegJsox4UNIRNTscjDDFzp-pBzPxKUd15U2pCWMmlDwHBJcxultLwPXlJuL8do_uWobfa__Xv_25e7D3dbTZt8cEvjAayYch1uH7exBOuwPXas3fNdMlkkodW7ZJuMF3ze84ewN24D2_C7kConDbWFqqtTQ4rypEgLW7AIL4nLZZvbPriiC01O0cj56uof1xvw-Vpm-whWy6o0m0AEVQMtZSp4FnGT0lgxLqQ9fLNe1Ix5QDssJFlLzW4rhHxLelLpBj4Jwiex8EmoB2_6W84cL8lVnbc6ZCStiKqTBSw8eNk3o3CxHiNVmurC9hGUiYAJ6cFjh8d-NBYHksci8EAsIbXvYInLl1vK4qQhMI-EkDiyBzsdpv94rX9N4snVk3gBdw4mx8NkeDg6egprqNdKF1y_Bauz8wvzDG5lP2ZFff68WbMEvlw31H8DD6p4OQ
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgiouPMqjgQJGgh6gUR3HWTsHhBDtiqpllUOR9hac2KGR2qQ0W9D-NX4dY-exLBW99cAtUiYPJ9_YM56ZbwBeyYgHueaBrwNhfM6z2M8yRf0iZiZXcVxkhfvTh2IykdNpnKzAr74WxqZV9nOim6h1nds98h1L44LGQyT4TtGlRSS74_dn333bQcpGWvt2Gi1EDsz8J7pvzbv9XfzXrxkb7x19_OR3HQb8PApHM79gWSRddaqiNIu1lgrtAXTDZY7ufaFw7aZGhQZtCqmpCnhh0J3RAddCRTwchXjfG3BThCiHuiSmYlGTGbRt7EPO_UhQ3kdUqSMwZdKmg6F6c5uxtLwmXjJ0L-dr_hW0dWvh-O7__BXvwZ3OAicfWpW5DyumWoe1z12OwTpsJS2b93ybHC2K05ptskWSBc_3_AHsJV3CG34jUhfEUV6opj41pKyOy6y0jYzwkLQ1bnMrg5peanKKzs-3ti9y8xC-XMtoH8FqVVdmA4igaqSlzATPI24yGivGhbSbcja6mjMPaI-LNO8o223nkJN0IJt2UEoRSqmFUko9eDNcctbylVwlvNmjJO2mriZdQMSDl8NpnHRsJElVpr6wMoIyETAhPXjcYnN4GosDyWMReCCWUDsIWELz5TNVeeyIzSMhJD7Zg7c9vv94rX8N4snVg3gBa4jw9HB_cvAUbqO5K9uc-01YnZ1fmGdwK_8xK5vz5059CXy9bqT_BkHZgO0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Positioning+of+proteasome+inhibitors+in+therapy+of+solid+malignancies&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Roeten%2C+Margot+S.+F.&rft.au=Cloos%2C+Jacqueline&rft.au=Jansen%2C+Gerrit&rft.date=2018-02-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=0344-5704&rft.eissn=1432-0843&rft.volume=81&rft.issue=2&rft.spage=227&rft.epage=243&rft_id=info:doi/10.1007%2Fs00280-017-3489-0&rft_id=info%3Apmid%2F29184971&rft.externalDocID=PMC5778165
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon